Leiden, The Netherlands, 8 July 2022 - VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announced it will present new preclinical data on the pharmacodynamics, toxicokinetics, and safety of VMX-C001, its lead compound, at the 2022 ISTH (International Society on Thrombosis and Haemostasis) Congress in London.

VarmX will deliver an oral presentation on Sunday, 10 July at 15.15-15.30 BST, and will showcase a poster on Tuesday 12 July at 18.30-19.30 BST.

VarmX is developing VMX-C001, a modified recombinant blood factor X, for the treatment of severe spontaneous bleeding and the prevention of bleeding during surgery in patients taking direct oral factor FXa-inhibiting anticoagulants (DOACs). Last December, the Company announced treatment of the first subjects in its first-in-human study for VMX-C001.

In the oral presentation, VarmX’s Director of Research, Daniël Verhoef will present new preclinical data demonstrating that VMX-C001 displays a favorable pharmacodynamic profile in animal models and is an effective factor Xa inhibitor reversal agent. The abstract, which was selected by the conference organizers for oral presentation, is available here.

Dr. Daniël Verhoef will also present a poster showcasing new preclinical data on the safety and toxicokinetics of VMX-C001 as an intravenous bypassing agent for factor Xa inhibitors. The abstract is available 
here.

Pieter Reitsma, Founder and CSO of VarmX, commented: “We are happy and grateful that the ISTH Congress organizers have recognized the impact and importance of the new preclinical data package that details pharmacological and safety aspects of VMX-C001. This work has paved the way to initiation of our first-in-human study of VMX-C001, which is now ongoing, and the resulting transition of VarmX from a preclinical into a clinical company.”

Oral presentation details

Title: VMX-C001 is an effective factor Xa inhibitor reversal agent and displays a favorable pharmacodynamic profile in animal models

Session: Managing Coagulopathy

Date: 10 July 2022

Time: 15.15-15.30 BST

Location: ExCel Center, ICC Capital Suite Room 14-16

Poster presentation details

Title: Preclinical safety and toxicokinetics of VMX-C001 - an intravenous bypassing agent for factor Xa inhibitors

Session: Poster Networking Session

Date: 12 July 2022

Time: 18.30-19.30 BST

Location: Exhibition 

ENDS

For further information, please contact:

VarmX B.V.

Dr. Jan Öhrström, CEO

Instinctif Partners (media enquiries)

Melanie Toyne-Sewell / Katie Duffell

Tel: +44 20 7457 2020

Email: VarmX@instinctif.com

Notes to Editors

About VarmX 

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center (LUMC), founded in 2016 by Professor Pieter Reitsma, a world leading expert in hemostasis and thrombosis. VarmX’s lead compound VMX-C001 is a modified recombinant blood factor Xa based on the venom of the Australian brown snake, Pseudonaja textilis. The compound is being developed for the treatment of severe spontaneous bleeding in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. In July 2020, the Company raised €32m in a series B financing, supported by a strong syndicate of investors including Ysios Capital, INKEF Capital, Lundbeckfonden Ventures, LSP, BioGeneration Ventures and the regional economic development fund, InnovationQuarter. For more information: www.varmx.com

This website uses functional and analytical cookies. Accept Deny